Drug profile · INN
larotrectinib sulfate
VITRAKVI
larotrectinib sulfate (VITRAKVI) is a neurotrophic tyrosine kinase receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — larotrectinib sulfate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
larotrectinib sulfate (VITRAKVI) is a neurotrophic tyrosine kinase receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Neurotrophic tyrosine kinase receptor inhibitor
Primary target: Neurotrophic tyrosine kinase receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is larotrectinib sulfate?
larotrectinib sulfate (VITRAKVI) is a neurotrophic tyrosine kinase receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for larotrectinib sulfate?
VITRAKVI is a marketed brand name for larotrectinib sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of larotrectinib sulfate?
larotrectinib sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.